Focus: ReCode Therapeutics is a public biotechnology company focused on nucleic acid therapeutic delivery platforms for rare and metabolic diseases. Founded in 2010 and headquartered in Menlo Park, CA, the company operates as a clinical-stage developer with early-phase pipeline assets.
Profile data last refreshed 17h ago · AI intelligence enriched 1mo ago
Best suited for researchers and development professionals passionate about nucleic acid therapeutics who can tolerate pre-commercial risk in exchange for deep technical ownership and upside equity participation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ReCode Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ReCode Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Indivior Pharmaceuticals, Inc. (INDV) (CIK 0001625297) — FORM 8-K
FORM 8-K
ReCode Therapeutics lines up new CEO, funding and partnership - The Business Journals
ReCode Therapeutics lines up new CEO, funding and partnership The Business Journals
ReCode Therapeutics Secures Cystic Fibrosis Foundation Funding And Names Heather Clark CEO - Pulse 2.0
ReCode Therapeutics Secures Cystic Fibrosis Foundation Funding And Names Heather Clark CEO Pulse 2.0
ReCode Therapeutics Secures Cystic Fibrosis Foundation Funding And Names Heather Clark CEO - Pulse 2.0
ReCode Therapeutics Secures Cystic Fibrosis Foundation Funding And Names Heather Clark CEO Pulse 2.0
ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition - Business Wire
ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition Business Wire
ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition - BioSpace
ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition BioSpace
Showing 6 of 9 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics (†).
Dual SORT LNPs for multi-organ base editing.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo